Exploring new cancer treatment targets for acute myeloid leukemia.
Official title: Structural surfaceomics to probe conformation-selective immunotherapy targets
Funded at University of California, San Francisco · NIH-10904543 · Data updated 2026-11-12
This study is exploring new ways to treat acute myeloid leukemia (AML) by finding special proteins on cancer cells that can be targeted by a type of immune therapy, which could lead to safer and more effective treatments for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $550,255 |
| NIH project number | 1R01CA290875-01 |
| Project ID | NIH-10904543 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with acute myeloid leukemia who are seeking new treatment options.
✕Less likely to help
Patients with other types of cancer or those who do not have acute myeloid leukemia may not benefit from this research.
What this research studies
This research investigates innovative immunotherapy targets for acute myeloid leukemia (AML) by utilizing a novel technology called structural surfaceomics. This approach focuses on identifying unique, cancer-specific conformations of plasma membrane proteins that can serve as effective targets for treatment. By analyzing AML models and validating findings with patient samples, the research aims to develop engineered T-cell therapies that specifically target these proteins, potentially leading to safer and more effective treatment options for patients with AML.
Why it matters
Potential benefit: If successful, this research could lead to a new, more effective immunotherapy for patients with acute myeloid leukemia, improving treatment outcomes and reducing side effects.
How similar studies have gone: This approach is innovative and has not been widely tested in previous research, making it a novel exploration in the field of cancer immunotherapy.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Wiita, Arun P. — University of California, San Francisco
- Study coordinator: Wiita, Arun P.
Related research
Other NIH-funded projects on the same topics.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
A center focused on immunotherapy for pediatric cancers.
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
-
Algorithms to find HLA-E neoantigens for cancer immunotherapy
Aims to develop computer methods to discover tumor-specific targets presented by HLA-E to guide new T cell therapies for cancer.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
How CRISPR-based gene activation could shape immunotherapy responses in clear cell cancers
A research project at Stanford is using CRISPR-based gene activation to understand why some clear cell ovarian and kidney cancers respond to immunotherapy while others do not.
-
Hybrid biomaterial system to boost immunotherapy for rheumatoid arthritis
A new, patient-facing immunotherapy approach uses specialized particles to retrain the immune system to calm RA in adults.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.